GREEN PLANET MICROCAPS
ESG MICROCAP SPECIALISTS
Our treasure chest is filled with inspiring young companies that have innovative solutions to address a clean, low-carbon environment and to provide disruptive technologies to make life better
TOMORROW'S WINNERS TODAY
New Way to Treat Cancer Could Convert Cancer Cells Back into Normal Heathy Cells
NANOCAP PROPANC BIOPHARMA IS DEVELOPING ‘PRP’ FOR PROMISING NEW WAY TO TREAT CANCER
-
Proof of concept study demonstrated 41% of 46 terminal patients treated with Propanc PRP exceeded life expectancy without any serious adverse events
-
PRP has demonstrated a unique ability to convert cancerous cells back to healthy cells. Post-treatment data shows Colorectal and Pancreatic cancer cells returned to homeostasis (normal cells)
-
National Center for Biotechnology Information published a paper reporting evidence that Trypsinogen and chymotrypsinogen (the ingredients in Propanc PRP) demonstrate anti-tumourigenic potential and sensitizes Cancer Stem Cells which may allow chemotherapy and radiotherapy to be more effective
-
Propanc has optimized and improved PRP for improved results and is ready to initiate a Phase 1b clinical study in 30 - 40 patients to study the safety and efficacy of PRP with results expected in 2025
-
Initially targeting Pancreatic and Ovarian cancers with combined TAM of $14.3B and long-term strategy of targeting metastatic solid tumors (~$111B TAM)
-
Competing cancer therapeutics companies in similar early stages typically support market caps of several hundred million dollars
-
Propanc Biopharma has 93 patents and has raised $23 million to date with a market cap of approximately $200,000.
Few will argue that the need for more effective cancer treatment is large and growing every day. Despite significant advancements in chemotherapy, radiation, and immunotherapies, cancer remains one of the leading causes of death and is likely to impact each, and every one of us, or a family member. Cancer deaths continue to rise sharply as CNN recently reported, “Global cancer deaths among men projected to increase by 93% by 2050”.
Advancements in cancer treatment will come from small startups, not big pharma. The drug giants rarely innovate new drugs for anything because they are too risky to develop and their business model is to always avoid risk whenever possible. New drugs are almost always invented and developed by small, or start-up biotech companies, and then big drug companies typically license or buy the drug from the little company after it is derisked by being approved by the FDA or some other foreign regulatory agency. The end goal of little start-ups is to become a big company. If they successfully develop a drug for large markets such as cancer therapeutics and then license it to a large drug company, they will have succeeded with enormous returns for their investors.
Propanc Biopharma is exactly that very small startup that has discovered what appears to be a candidate for a very promising new way to treat cancer.
Their first Proof of Concept study demonstrated that 41% of 46 terminal patients treated with Propanc PRP exceeded life expectancy without any serious adverse events. And their drug PRP was the first unrefined version that nonetheless still yielded remarkable results by significantly extending life expectancy of terminal cancer patients.
The following graph demonstrates a wide spectrum efficacy against several different cancer types.
How Does Propanc PRP Work?
This short video will save time explaining how and why Propanc PRP works:
Why should investors consider Propanc Biopharma?
Upcoming Phase 1b clinical study is expected to outperform the strong results of the first Compassionate Use study for the following reasons:
Examples of 3 competing cancer drug developers in early stages from Phase 1 to Phase 3 indicate market caps plus or minus 100 times greater than Propanc Biopharma
Readers are encouraged and invited to visit https://www.propanc.com where valuable detailed information can be found.
Conclusion
Small start-ups like Propanc Biopharma, Inc. are attractive and can also be risky. Early investors in Propanc Biopharma have the advantage of being able to invest at exceptionally low prices that are hard to find for companies that have demonstrated compelling Proof of Concept studies, that have already raised over $23 million, that have support from leading experts in their field, and that have 93 patents filed. Propanc Biopharma appears to be a strong candidate for consideration.
Legal Disclosures and Disclaimers
Green Planet Microcaps is not a registered investment adviser. The information that we provide from our website or newsletters is not, and should not be construed in any manner, to be investment advice. All opinions and information provided on this site are for educational and research purposes. Green Planet Microcaps encourages all readers to do their own due diligence and research when determining which investment strategies are best suited for them or to seek the advice of an investment professional.
Any information provided by Green Planet Microcaps should not be construed by any subscriber or prospective subscriber as a solicitation by Green Planet Microcaps to effect, or attempt to effect, any transaction in any security. Investments in the securities markets, and especially in private securities of small start-up companies, are incredibly and highly speculative and involve substantial risk that your entire investment could be lost. The information that we provide or that is derived from our website and/or newsletters should not be a substitute for advice from an investment professional. We encourage you to obtain personal advice from your professional investment advisor and to make independent investigations before acting on the information that you obtain from Green Planet Microcaps or derive from our website and/or newsletters. Only you can determine what level of risk is appropriate for you.
Specifically, we advise all readers and subscribers to seek advice from a registered professional securities representative before deciding to purchase or trade in stocks or any securities presented on this website and/or in a particular newsletter. All information provided regarding the companies featured comes from the companies themselves, SEC filings, news releases, private placement memoranda, company websites as well as other sources of publicly available information. The profiles of these highlighted public and private companies are not in any way a solicitation or recommendation to buy, sell, or hold these or any other securities.
Most of the information on our website and/or newsletters or that we otherwise provide is derived directly from information published by the companies on which we report and/or from other sources we believe are reliable, without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. The information may contain discussions of, or provide access to, certain positions and recommendations as of a specific date. Due to various factors, including, but not limited to, changing market conditions, such discussions and positions/recommendations may no longer be reflective of current discussions and positions/recommendations. We do not in any way warrant or guarantee the success of nor endorse any action which you take in reliance on the information that we provide or that is derived from our website.
Investors should not rely solely on the information contained on this website or in any specific newsletter. Rather, investors should use the information contained on this Website and/or in newsletters as a starting point for doing additional independent research on the featured private and public companies. The advertisements within this newsletter are not to be construed as offers to purchase securities in the companies which may be the subject of such advertisements pursuant to federal or state law or the laws of any foreign jurisdiction.
Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects’”, “will,” “anticipates,” “estimates,” “believes,” “understands” or that by statements indicating certain actions “may,” “could,” or “might” occur. There is no guarantee past performance will be indicative of future results. The accuracy or completeness of the information in this newsletter is only as reliable as the sources they were obtained from. Green Planet Microcaps was compensated for this article and will not be liable for any consequential, incidental, punitive, special, exemplary or indirect damages resulting directly or indirectly from the use of or reliance upon any material provided by Green Planet Microcaps or derived from Green Planet Microcap’s website and/or newsletters. Green Planet Microcaps shall not be responsible or liable for any loss or damages related to, either directly or indirectly, (1) any decline in market value or loss of any investment; (2) a subscriber’s inability to use or any delay in accessing Green Planet Microcaps website or any other source of material provided by Green Planet Microcaps including newsletters; (3) any absence of material on Green Planet Microcaps; (4) Green Planet Microcaps failure to deliver or delay in delivering any material or (5) any kind of error in transmission of material. Green Planet Microcaps and each subscriber acknowledge that, without limitation, the above-enumerated conditions cannot be the probable result of any breach of any agreement between Green Planet Microcaps and the subscriber.
Green Planet Microcaps is not affiliated with any brokerage firm and does not endorse or recommend any specific brokerage firm. Green Planet Microcaps is not and will not be responsible for any trades made by a broker on the subscriber’s behalf under any circumstances.